Status:
UNKNOWN
Validation Study of a New Digital Treatment Test
Lead Sponsor:
Braingaze
Conditions:
Alzheimer Disease
MCI
Eligibility:
All Genders
50-85 years
Phase:
NA
Brief Summary
Oculomotor behavior and cognitive processing of visual information are intimately connected. AD patients show ocular movement problems. Oculomotor deficits are broad consisting mainly of different sac...
Eligibility Criteria
Inclusion
- 1\) Clinical diagnosis of MCI or AD
Exclusion
- Severe cognitive deterioration
- History of neurological disease with clinically relevant impact on cognition
- Severe psychiatric disorder
- Incidental structural brain findings with impact on cognitive impairment
- Presence of relevant visual problems
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04897464
Start Date
June 1 2021
End Date
May 31 2022
Last Update
May 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Braingaze
Mataró, Barcelona, Spain, 08302